DSE : SQURPHARMA

Square Pharmaceuticals PLC. — Key statistics

Pharmaceutical Preparations · Bangladesh

Last price 218.5 BDT (At close: Oct 29, 2026) · Market cap 193.69B

Latest research: Square Pharmaceuticals valuation report: fair value BDT 218–397 (Oct 2026) · Square Pharmaceuticals: fair value BDT 218–397, base 316; cash and investments are BDT 112 a share

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Technical report: trend, RSI, support and resistance, charts

Key statistics

Valuation

Measure	Value
Market Cap	193.69B
Enterprise Value	121.48B

Dates

Measure	Value
Earnings Date	Nov 5, 2026
Ex-Dividend Date	Nov 17, 2026

Measure	Value
Current Share Class	886.45M
Shares Outstanding	886.45M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.04%
Owned by Insiders (%)	44.10%
Owned by Institutions (%)	3.02%
Float	495.49M

Ratios

Measure	Value
PE Ratio	7.49
Forward PE	6.76
PS Ratio	2.32
PB Ratio	1.29
P/TBV Ratio	1.29
P/FCF Ratio	13.86
P/OCF Ratio	8.69
PEG Ratio	n/a

Evratios

Measure	Value
EV / Earnings	4.70
EV / Sales	1.45
EV / EBITDA	4.55
EV / EBIT	4.96
EV / FCF	8.69

Financialposition

Measure	Value
Current Ratio	13.78
Quick Ratio	11.26
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	0.03
Interest Coverage	185.75

Financialefficiency

Measure	Value
Return on Equity (ROE)	18.14%
Return on Assets (ROA)	9.10%
Return on Invested Capital (ROIC)	20.48%
Return on Capital Employed (ROCE)	14.36%
Weighted Average Cost of Capital (WACC)	4.91%
Revenue Per Employee	5.24M
Profits Per Employee	1.62M
Employee Count	15,937
Asset Turnover	0.56
Inventory Turnover	3.19

Taxes

Measure	Value
Income Tax	5.65B
Effective Tax Rate	17.93%

Stockprice

Measure	Value
Beta (5Y)	0.11
52-Week Price Change	+2.63%
50-Day Moving Average	217.22
200-Day Moving Average	216.07
Relative Strength Index (RSI)	53.28
Average Volume (20 Days)	214,903

Shortselling

Measure	Value
Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Incomestatement

Measure	Value
Revenue	83.53B
Gross Profit	40.29B
Operating Income	21.82B
Pretax Income	31.52B
Net Income	25.86B
EBITDA	24.03B
EBIT	21.82B
Earnings Per Share (EPS)	29.18

Balancesheet

Measure	Value
Cash & Cash Equivalents	60.82B
Total Debt	356.03M
Net Cash	72.22B
Net Cash Per Share	81.47
Equity (Book Value)	150.51B
Book Value Per Share	169.78
Working Capital	76.58B

Cashflow

Measure	Value
Operating Cash Flow	22.30B
Capital Expenditures	-8.32B
Depreciation & Amortization	2.21B
Net Borrowing	-621.77M
Free Cash Flow	13.98B
FCF Per Share	15.77

Margins

Measure	Value
Gross Margin	48.24%
Operating Margin	26.12%
Pretax Margin	37.73%
Profit Margin	30.96%
EBITDA Margin	28.77%
EBIT Margin	26.12%
FCF Margin	16.74%

Dividends

Measure	Value
Dividend Per Share	12.00
Dividend Yield	5.49%
Dividend Growth (YoY)	8.33%
Years of Dividend Growth	8
Payout Ratio	40.97%
FCF Payout Ratio	82.44%
Buyback Yield	n/a
Shareholder Yield	5.49%
Earnings Yield	13.35%
FCF Yield	7.22%

Analystforecasts

Measure	Value
Price Target	352.20
Price Target Difference	61.19%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (3Y)	11.06%
EPS Growth Forecast (3Y)	11.17%

Stocksplits

Measure	Value
Last Split Date	Nov 23, 2020
Split Type	Forward
Split Ratio	1.05

Scores

Measure	Value
Altman Z-Score	18.17
Piotroski F-Score	5

Fairvalue

Measure	Value
Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside